Literature DB >> 21524657

The Aicardi-Goutières syndrome. Molecular and clinical features of RNAse deficiency and microRNA overload.

A Pulliero1, E Fazzi, C Cartiglia, S Orcesi, U Balottin, C Uggetti, R La Piana, I Olivieri, J Galli, A Izzotti.   

Abstract

Intracellular RNAses are involved in various functions, including microRNA maturation and turnover. Mutations occurring in genes encoding RNAses cause Aicardi-Goutiéres syndrome (AGS). AGS mutations silence RNAse activity, thus inducing accumulation of endogenous RNAs, mainly consisting of short RNAs and microRNAs. Overload of intracellular RNA triggers Toll like receptor-dependent interferon-alpha production in the brain, which in turn activates neurotoxic lymphocytes and inhibits angiogenesis thus inducing the typical clinical phenotype of AGS. However, these pathogenic mechanisms are attenuated after three years of age by the endogenous production of DNAJP58IPK and Cystatin F, which arrest AGS progression. Because RNAses are involved in microRNA turnover, we evaluated the expression of 957 microRNAs in lymphocytes from AGS patients and control patients. Our results indicate that microRNA overload occurs in AGS patients. This upregulation inhibits microRNA turnover impeding the synthesis of the novel microRNAs required for the differentiation and myelination of the brain during the initial period of postnatal life. These pathogenic mechanisms result in AGS, a neurological syndrome characterized by irritability, mild hyperpyrexia, pyramidal and extrapyramidal signs, and spastic-dystonic tetraplegia. Typical cerebrospinal fluid alterations include lymphocytosis and elevated interferon-alpha levels. Brain imaging demonstrates cerebral calcifications, white matter abnormalities, and progressive cerebral atrophy.Thus, evidence exists that mutations silencing intracellular RNases affect microRNA turnover resulting in the severe clinical consequences in the brain characterizing the clinical feature of AGS. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524657     DOI: 10.1016/j.mrfmmm.2011.03.018

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  14 in total

1.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

2.  MicroRNAs in cancer treatment and prognosis.

Authors:  Cláudia Regina Gasque Schoof; Eder Leite da Silva Botelho; Alberto Izzotti; Luciana Dos Reis Vasques
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

3.  Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation.

Authors:  Sebastiano La Maestra; Guido Frosina; Rosanna T Micale; Chiara D'Oria; Silvano Garibaldi; Antonio Daga; Alessandra Pulliero; Alberto Izzotti
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

4.  MicroRNAs in Neurotoxicity.

Authors:  Prameet Kaur; Arunmozhiarasi Armugam; Kandiah Jeyaseelan
Journal:  J Toxicol       Date:  2012-03-06

Review 5.  Primary immunodeficiency diseases associated with neurologic manifestations.

Authors:  Soodabeh Fazeli Dehkordy; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2011-10-26       Impact factor: 8.542

Review 6.  Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers.

Authors:  Jian Shi
Journal:  Acta Pharmacol Sin       Date:  2014-12-29       Impact factor: 6.150

7.  Modulation of genomic and epigenetic end-points by celecoxib.

Authors:  Alberto Izzotti; Sebastiano La Maestra; Rosanna T Micale; Alessandra Pulliero; Marta Geretto; Roumen Balansky; Silvio De Flora
Journal:  Oncotarget       Date:  2018-09-14

8.  Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses.

Authors:  Eda K Holl; Kara L Shumansky; George Pitoc; Elizabeth Ramsburg; Bruce A Sullenger
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

9.  Aicardi-Goutières Syndrome: Brief Case Report.

Authors:  Luis Rafael Moscote-Salazar; Willem Guillermo Calderon-Miranda; Ray Vicente Deluquez Baute; Amit Agrawal; Guru Dutta Satyarthee; Johana Maraby-Salgado; Huber Said Padilla-Zambrano; Daniela Lopez-Cepeda; Alfonso Pacheco-Hernandez; Andrei F Joaquim
Journal:  J Pediatr Neurosci       Date:  2018 Jan-Mar

Review 10.  Neurological Manifestations of Primary Immunodeficiencies.

Authors:  Zahra Chavoshzadeh; Amir Hashemitari; Sepideh Darougar
Journal:  Iran J Child Neurol       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.